A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1327-1331

  Blay, J Y ^a,h   Le Cesne, A ^b   Verweij, J ^c   Scurr, M ^d   Seynaeve, C ^c   Bonvalot, S ^b   Hogendoorn, P ^e   Jimeno, J ^f   Evrard, V ^g   Van Glabbeke, M ^g   Judson, I ^d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f PHARMAMAR S A   (Spain)

^g EORTC DATA CENTER   (Belgium)

^h CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; TRABECTEDIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; SARCOMA; SURVIVAL RATE; TETRAHYDROISOQUINOLINES; TREATMENT FAILURE;

EID: 2942571277     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.005     Document Type: Article

References (35)

1. Berman J., O'Leary T.J. Gastrointestinal stromal tumor workshop. Hum. Pathol. 32:2001;578-582
2. Pidhorecky I., Cheney R.T., Kraybill W.G. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann. Surg. Oncol. 7:2000;705-712
3. Miettinen M., Sarlomo-Rikala M., Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum. Pathol. 30:1999;1213-1220
4. Nishida T., Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol. Histopathol. 15:2000;1293-1301
5. Rubin B.P., Fletcher J.A. Molecular insights into the histogenesis and pathogenesis of gastrointestinal tumors. Int. J. Surg. Pathol. 8:2000;5-10
6. Fletcher C.D.M., Berman J.J., Corless C.L., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33:2002;459-465
7. Miettinen M., Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 438:2001;1-12
8. Hirota S., Osizaki K., Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580
9. Nishida T., Hirota S., Taniguchi M. Familial gastrointestinal stromal tumours with germline mutations of the KIT gene. Nat. Genet. 19:1998;323-324
10. Hirota S., Okazaki T., Kitamura Y. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am. J. Surg. Pathol. 24:2000;326-327
11. Lux M.L., Rubin B.P., Biase T.L. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 156:2000;791-795
12. Isozaki K., Terris B., Belghiti J. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am. J. Pathol. 157:2000;1581-1585
13. Heinrich M.C., Griffith D.J., Druker B.J. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932
14. Rubin B.P., Singer S., Tsao C. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121
15. Joensuu H., Roberts P.J., Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:2001;1052-1056
16. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. N. Engl. J. Med. 358:2001;1421-1423
17. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480
18. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 39:2003;2006-2011
19. Benjamin R.S., Rankin C., Fletcher C., et al. Phase III dose randomized study of imatinib mesylate for GIST: intergroup SO033 early results. Proc. Am. Soc. Clin. Oncol. 22:2003;814. (abstract 3271)
20. Verweij J., Casali P., Zalcberg J., et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointextinal stromal tumors: interim results of a randomized phase III trial of the EORTC STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. 22:2003;814. (abstract 3272)
21. O'Bryan R.M., Baker L.H., Gottlieb J.B., et al. Dose response evaluation of adriamycin in neoplasma. Cancer. 39:1977;1940-1948
22. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first line treatment of advanced soft tissue sarcomas. A randomized study of the EORTC Soft tissue and bone sarcoma group. J. Clin. Oncol. 13:1995;1537-1545
23. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2, 185 patients treated with anthracycline-containing first-line regimens. A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J. Clin. Oncol. 17:1999;150-157
24. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 18:2002;3898-3905
25. Nielsen O.S., Blay J.Y., Judson I.R., et al. Metastatic soft tissue sarcoma in adults. Prognostic and treatment options. Am J Cancer. 2:2003;1-12
26. Plaat B.E., Hollema H., Molenaar W.M. Soft tissue leiomyosarcomas and malignant gastrointestinal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol. 18:2000;3211-3220
27. Delaloge S., Yovine A., Taamma A., et al. ET-743: a marine derived compound in advanced pretreated sarcoma patients - preliminary evidence of activity. J. Clin. Oncol. 19:2001;1248-1255
28. Demetri G.G.D., Seiden M., Garcia-Carbonero A., et al. ET-743 shows promising activity in distinct populations of sarcoma patients: summary of 3 phase II trials. Proc. Am. Soc. Clin. Oncol. 19:2000;553a. (2177)
29. Lopez-Martin J.A., Verweij J., Nieto A., et al. Is progression free survival at 6 months in advanced soft tissue sarcoma a measure of clinical benefit? an exploratory analysis of tumor growth rate variation induced by ET743. Proc. Am. Soc. Clin. Oncol. 22:2003;821. (abstract 3293)
30. Van Glabbeke M., Verweij J., Judson I.R., et al. Progression free survival rate as principal endpoint for phase II trial in soft tissue sarcomas. Eur. J. Cancer. 2002;543-549
31. Miller A.B., Hogestraten B., Staquet M., Winkler A. Reporting results of clinical trials. Cancer. 47:1981;207-214
32. Gwyther S.J., Nielsen O.S., Judson I.R., van Glabbeke M., Verweij J. Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Anticancer Drugs. 11:2000;433-437
33. Simond R. Optimal two stage designs for phase II clinical trials. Control Clin. Trials. 10:1989;1-10
34. Demetri G.D., Georges S., Heinrich M., et al. Clinical activity and tolerability of the multitargeted tyrosine kinase inhibitor SU11248 in patients with metastatic gastrointestinal stromal tumors refractory to imatinib mesylate. Proc. Am. Soc. Clin. Oncol. 22:2003;814. (abstract 3273)
35. Ryan D.P., Puchalski T., Supko J.G., et al. A phase II and pharmacokinetic study of ET743 in patients with gastrointestinal stromal tumors. The Oncologist. 7:2002;531-538